Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype

NCT04718103 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT04718103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04718103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
February 4, 2021
Completion date
April 11, 2024
Enrollment
397 (actual)
Sites
129

Conditions

As the registry lists them; a condition with its own page is linked.

asthma